Skip to search formSkip to main contentSkip to account menu

eptifibatide

Known as: eptifibatide [Chemical/Ingredient], L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-, cyclic(1-6)-disulfide, epifibatide 
A cyclical heptapeptide with anticoagulant activity. Eptifibatide selectively and reversibly binds to and blocks the platelet glycoprotein IIb/IIIa… 
National Institutes of Health

Related topics

Related topics

17 relations
100 ML eptifibatide 0.75 MG/ML Injection100 ML eptifibatide 0.75 MG/ML Injection [Integrilin]Angina, UnstableCerebral Infarction

Narrower (2)

IntegrilinIntrifiban

Broader (2)

PeptidesPlatelet Aggregation Inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Bridging Experience With Eptifibatide After Stent Implantation.
BACKGROUND Patients who have undergone intracoronary stent implantation often require surgery within the first year after the… 
Review
2015
Review
2015
Abstract T P3: Safety of Eptifibatide after Full Dose IV tPA and Endovascular Treatment for Ischemic Stroke
Background and Objective: The safety of eptifibatide in combination with IV tPA for ischemic stroke has recently been… 
2015
2015
Pharmaceutical Analysis of Eptifibatide via Simple, Rapid, Economical UV-Spectrophotometric Methods
eptifibatide is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class. Pharmaceutically it is applied to reduce the… 
2009
2009
Streamlining the design of promising clinical trials: in-vitro testing of antithrombotic regimens and multiple agonists of platelet activation
Platelets are activated in vivo by multiple agonists; however, platelet function testing in vitro has been performed… 
2006
2006
[Glycoprotein IIb/IIIa antagonist eptifibatide in acute coronary syndrome without elevation of ST segment].
Abstract Clinical effects of glycoprotein (GP) IIb-IIIa antagonist eptifibatide (Integrilin) and its inhibitory effects on… 
2005
2005
The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention
ObjectiveTo characterize effects of bivalirudin compared with unfractionated heparin plus eptifibatide on inflammation, and… 
2004
2004
Efficiency in clinical research: assessment in vitro of potential anti-thrombotic drug interactions
ObjectiveTo determine whether testing in vitro of combinations of anti-thrombotic agents can identify potentially important… 
2003
2003
Antithrombozytärer Effekt von Abciximab, Tirofiban und Eptifibatide bei Patienten nach koronarer Stentimplantation
Diese prospektive, randomisierte Studie prufte den Einflus dreier Fibrinogenrezeptorblocker, Abciximab, Tirofiban und… 
Review
2001
Review
2001
Platelet Aggregation Inhibition with Glycoprotein IIb–IIIa Inhibitors
Inhibitors of the platelet receptor glycoprotein (GP) IIb–IIIa are a novel and potent class of antithrombotic drugs for the… 
2000
2000
High Platelet Count in Platelet-Rich Plasma Reduces Measured Platelet Inhibition by Abciximab but not Tirofiban nor Eptifibatide Glycoprotein IIb/IIIa Receptor Antagonists
We evaluated the differential effect of platelet count in platelet-rich plasma (PRP) on the level of ex vivo inhibition of…